Medulloblastoma - Pipeline Review, H1 2016
SKU ID :GMD-10193477 | Published Date: 08-Jun-2016 | No. of pages: 96Description
TOC
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Medulloblastoma Overview 9
Therapeutics Development 10
Pipeline Products for Medulloblastoma - Overview 10
Pipeline Products for Medulloblastoma - Comparative Analysis 11
Medulloblastoma - Therapeutics under Development by Companies 12
Medulloblastoma - Therapeutics under Investigation by Universities/Institutes 13
Medulloblastoma - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Medulloblastoma - Products under Development by Companies 17
Medulloblastoma - Products under Investigation by Universities/Institutes 18
Medulloblastoma - Companies Involved in Therapeutics Development 19
Bayer AG 19
DelMar Pharmaceuticals, Inc. 20
Ignyta, Inc. 21
Lipocure Ltd. 22
MacroGenics, Inc. 23
Medicenna Therapeutics, Inc. 24
MEI Pharma, Inc. 25
Novartis AG 26
Novogen Limited 27
Progenics Pharmaceuticals, Inc. 28
Stemline Therapeutics, Inc. 29
Takeda Pharmaceutical Company Limited 30
Medulloblastoma - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
(topotecan hydrochloride + vincristine sulfate) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
dianhydrogalactitol - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Edotreotide Labeled Yttrium 90 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
irinotecan hydrochloride + TBio-02 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
LEQ-506 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
MDNA-55 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma and Medulloblastoma - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
nifurtimox - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
nifurtimox SR - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
p28 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
pracinostat - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
siomycin A - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
SL-301 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
taladegib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
THR-317 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Trilexium - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
VMY-1103 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Medulloblastoma - Recent Pipeline Updates 71
Medulloblastoma - Dormant Projects 89
Medulloblastoma - Product Development Milestones 90
Featured News & Press Releases 90
Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083 90
Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant 91
Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors 91
Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors 93
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 95
Disclaimer 96
Tables & Figures
Companies
Bayer AG
DelMar Pharmaceuticals, Inc.
Ignyta, Inc.
Lipocure Ltd.
MacroGenics, Inc.
Medicenna Therapeutics, Inc.
MEI Pharma, Inc.
Novartis AG
Novogen Limited
Progenics Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
- PRICE
-
$2000$6000